1. Donanemab reduced brain amyloid levels over 76 weeks.
2. Lower amyloid levels aligned with slower cognitive decline.
3. Plasma p-tau217, p-tau181, and GFAP decreased with treatment.
4. No correlation was observed with neurofilament light chain.
5. Amyloid clearance was achieved in most treated patients.
6. Posttreatment amyloid may serve as a surrogate biomarker.

Source: JAMA Neurology